[Rho kinase--a new target for pharmacological treatment of an overactive bladder].
Rho kinase plays a key role in the regulation of smooth muscles contraction, including those of the urinary bladder detrusor. Rho kinase pathway modulates the level of phosphorylation of the myosin light chain, mainly through the inhibition of myosin phosphatase. Recent experimental data indicate that its role might be exacerbated in local and systemic pathological conditions which affect the bladder. It seems that Rho kinase inhibitors, such as Y27632, may turn out to be an effective group of drugs in pharmacotheraphy of an overactive bladder (OAB), which will influence the storage phase of the micturition cycle, without interfering with the physiological voiding.
Wróbel
Andrzej
A
II Katedra i Klinika Ginekologii Akademii Medycznej w Lublinie.
Adamiak
Aneta
A
Skorupski
Paweł
P
Rechberger
Tomasz
T
D000577:Amides / Q000627:therapeutic use*; D000818:Animals; D004789:Enzyme Activation; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D009119:Muscle Contraction / Q000187:drug effects; D009125:Muscle Relaxants, Central / Q000627:therapeutic use*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000502:physiology; D011725:Pyridines / Q000627:therapeutic use*; D001743:Urinary Bladder / Q000473:pathology / Q000502:physiology; D001745:Urinary Bladder Diseases / Q000188:drug therapy*
D000577:Amides; D004791:Enzyme Inhibitors; D009125:Muscle Relaxants, Central; D011725:Pyridines; C108830:Y 27632; D017346:Protein Serine-Threonine Kinases